Back to top
more

LeMaitre Vascular (LMAT)

(Delayed Data from NSDQ)

$89.04 USD

89.04
70,893

-0.82 (-0.91%)

Updated Aug 28, 2024 04:00 PM ET

After-Market: $89.05 +0.01 (0.01%) 7:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 39% (98 out of 251)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Acadia Healthcare Expands Behavioral Health Services in Iowa

by Zacks Equity Research

ACHC breaks ground on a new behavioral health hospital in Council Bluffs, addressing regional care shortages through a joint venture with Methodist Health System.

Ensign Group (ENSG) Up 50% in Past Year: More Growth on the Horizon?

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on the back of improved skilled services revenues, higher rental revenues and adequate operating cash flows.

Why You Should Add HCA Healthcare (HCA) to Your Portfolio Now

by Zacks Equity Research

HCA Healthcare (HCA) remains well-poised for growth on growing emergency room visits, buyouts and solid cash flows.

LeMaitre (LMAT) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Best Momentum Stock to Buy for August 6th

by Zacks Equity Research

HWKN, PPC and LMAT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 6, 2024.

LeMaitre Vascular (LMAT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 10.64% and 1.25%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

HLN vs. LMAT: Which Stock Is the Better Value Option?

by Zacks Equity Research

HLN vs. LMAT: Which Stock Is the Better Value Option?

Merit Medical (MMSI) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Merit Medical's (MMSI) strong product portfolio.

Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Intuitive Surgical (ISRG) Hits 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Intuitive Surgical's (ISRG) strength in robotics.

Encompass Health (EHC) Expands in Louisville With New Rehab Unit

by Zacks Equity Research

Encompass Health (EHC) and Baptist Health inaugurate a 40-bed inpatient rehabilitation hospital in Louisville, enhancing regional care and expanding EHC's network to 163 facilities.

GE HealthCare's (GEHC) New Tie-Up to Boost CVD Workflow

by Zacks Equity Research

GE HealthCare's (GEHC) latest collaboration is likely to enable clinicians to perform complex cardiology interventions with a high level of precision and improved image quality.

Encompass Health (EHC) Gains 30% in a Year: More Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is well-poised for growth on the back of sustained top-line growth, an aging U.S. population, frequent expansion initiatives and strong cash reserves.

LeMaitre (LMAT) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

LeMaitre (LMAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

New Strong Buy Stocks for June 21st

by Zacks Equity Research

ASYS, LAUR, ESLT, LNTH and LMAT have been added to the Zacks Rank #1 (Strong Buy) List on June 21, 2024.

Humana's (HUM) CenterWell Sets Foot in Asheville With New Centers

by Zacks Equity Research

Humana's (HUM) CenterWell Senior Primary Care announces the opening of two centers in Asheville, thus enhancing access to high-quality healthcare services and driving revenues of the CenterWell unit.

Compelling Reasons to Hold on to Ensign Group (ENSG) Stock

by Zacks Equity Research

Ensign Group (ENSG) remains well-poised for growth on the back of a growing revenue base, an expanding healthcare portfolio and solid cash reserves.

UnitedHealth Unit (UNH) Wins Medicaid Deal to Serve Kansas

by Zacks Equity Research

UnitedHealth Group (UNH) receives a contract from the State of Kansas to provide enhanced care to beneficiaries of the KanCare program and gain a greater Medicaid customer base.

All You Need to Know About LeMaitre (LMAT) Rating Upgrade to Strong Buy

by Zacks Equity Research

LeMaitre (LMAT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Why You Should Add Encompass Health (EHC) to Your Portfolio Now

by Zacks Equity Research

Encompass Health (EHC) remains well-poised for growth on the back of robust demand for effective inpatient rehabilitation services, joint ventures and solid cash reserves.

LeMaitre Vascular (LMAT) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

LeMaitre (LMAT) delivered earnings and revenue surprises of 12.82% and 3.65%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management

by Zacks Equity Research

AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.

Here's Why You Should Retain Medtronic (MDT) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Medtronic (MDT) due to the strength of its Neurosurgery and Cardiovascular portfolios.

Here's Why You Should Hold BD (BDX) Stock in Your Portfolio

by Zacks Equity Research

BD's (BDX) slew of product launches and strategic deals raises optimism about the stock.

Baxter's (BAX) New Injectables Aid Its Pharmaceutical Portfolio

by Zacks Equity Research

Baxter (BAX) unveils its five injectable products, which strengthen its emphasis on unique products and expand the pharmaceutical portfolio of the business in important therapeutic areas.